脑心通胶囊联合他汀类药物治疗高脂血症的系统评价

师帅; 褚瑜光; 张丽梅; 邱志凌; 汪九重; 胡元会; 纪鑫毓

引用本文:	师帅,褚瑜光,张丽梅,邱志凌,汪九重,胡元会,纪鑫毓.脑心通胶囊联合他汀类药物治疗高脂血症的系统评价[J].中国现代应用药学,2018,35(4):566-572.
	Shi Shuai,Chu Yuguang,Zhang Limei,Qiu Zhiling,Wang Jiuchong,Hu Yuanhui,Ji Xinyu.Systematic Review on Naoxintong Capsule Combined with Statins in Treatment of Hyperlipidemia[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(4):566-572.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2085次下载 1666次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
脑心通胶囊联合他汀类药物治疗高脂血症的系统评价
师帅¹, 褚瑜光¹, 张丽梅¹, 邱志凌¹, 汪九重¹, 胡元会¹, 纪鑫毓²
1.中国中医科学院广安门医院, 北京 100053;2.黑龙江省中医药科学院, 哈尔滨 150036

摘要:

目的系统评价脑心通胶囊联合他汀类药物治疗高脂血症的疗效和安全性。方法计算机检索Cochrane图书馆、PubMed、Embase、Medline、CNKI、CBM、VIP、万方等数据库，纳入相关随机对照研究（RCT），并进行评价，采用Revman 5.3软件分析数据。结果纳入14篇RCTs，共1 244例受试者。相比单独使用他汀类药物，脑心通联合他汀类药物的血脂总疗效提高[RR=1.20，95% CI（1.10，1.31），P<0.000 1]。治疗后总胆固醇水平低于对照组[WMD=-0.79，95% CI（-1.06，-0.53），P<0.000 01]，其中联合阿托伐他汀钙亚组异质性较低（P=0.09，I²=48%）。治疗后甘油三酯水平低于对照组[WMD=-0.68，95% CI（-0.92，-0.45），P<0.000 01]。治疗后高密度脂蛋白高于对照组[WMD=0.28，95% CI（0.18，0.37），P=0<0.000 01]。治疗后低密度脂蛋白水平低于对照组[WMD=-0.53，95% CI（-0.87，-0.18），P=0.003]。各组不良反应发生率差异均无统计学意义[RR=2.25，95% CI（0.71，7.16），P=0.17]。结论脑心通联合他汀类药物治疗高脂血症疗效明显，对TC、TG、HDL-C、LDL-C的改善有效，联合阿托伐他汀钙对TC改善的疗效较为确切，不良反应发生率未见与其他药物有明显差异，推荐临床联合应用，并建议补充更多高质量的相关研究。

关键词: 脑心通胶囊他汀类药物高脂血症系统评价

DOI：10.13748/j.cnki.issn1007-7693.2018.04.023

分类号:R969.4

基金项目:

Systematic Review on Naoxintong Capsule Combined with Statins in Treatment of Hyperlipidemia

Shi Shuai¹, Chu Yuguang¹, Zhang Limei¹, Qiu Zhiling¹, Wang Jiuchong¹, Hu Yuanhui¹, Ji Xinyu²

1.Guang'anmen Hospital, China Academy of Chinese medical science, Beijing 100053, China;2.Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China

Abstract:

OBJECTIVE To evaluate the efficacy and safety of Naoxintong capsule combined with statins in treating hyperlipidemia. METHODS We searched the Cochrane library, PubMed, Embase, Medline, CNKI, CBM, VIP and Wanfang database for RCTs, and analized by Revman 5.3 software. RESULTS Fourteen RCTs, a total of 1 244 subjects were included. Compared with the statins alone, the total effect of lipid of Naoxintong capsule combined with statins was higher than that in control group[RR=1.20, 95%CI (1.10, 1.31), P<0.000 1], the TC level after treatment of Naoxintong capsule combined with statins was lower than that in control group[WMD=-0.79, 95%CI (-1.06, -0.53), P<0.000 01], the heterogeneity of subgroup of Naoxintong capsule combined with Atorvastatin Calcium was low (P=0.09, I²=48%). The TG level after treatment of combined group was lower than control group[WMD=-0.68, 95%CI (-0.92, -0.45), P<0.000 01], the HDL-C level after treatment of combined group was higher than control group[WMD=0.28, 95%CI (0.18, 0.37), P=0<0.000 01], the LDL-C level after treatment of combined group was lower than that in control group[WMD=-0.53, 95%CI (-0.87, -0.18), P=0.003]. The incidence of adverse reactions in each group showed no significant difference[RR=2.25,95%CI (0.71,7.16),P=0.17]. CONCLUSION Naoxintong capsule combined with statins may more effectively improve hyperlipidemia, including TC, TG, HDL-C and LDL-C, the efficiency of combined with statins for TC is exactly and there is no significant difference of adverse reactions compared with other drugs, this article recommend it used in the treatment of hyperlipidemia in clinical and to add more high quality researches.

Key words: Naoxintong capsule statins hyperlipidemia systematic review